Clicky

News Feeds

HealthFolk's News section is a health news aggregator with a focus on Nigeria, and Africa as a whole.

[Seminar] Colorectal cancer

Tags: General

  • 1.
    • Bray F
    • Ferlay J
    • Soerjomataram I
    • Siegel RL
    • Torre LA
    • Jemal A

    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

    CA Cancer J Clin. 68: 394-424
  • 2.
    • Ferlay J
    • Ervik M
    • Lam F
    • et al.
    • IARC

    Cancer today (powered by GLOBOCAN 2018). IARC CancerBase number 15.

  • 3.
    • Arnold M
    • Sierra MS
    • Laversanne M
    • Soerjomataram I
    • Jemal A
    • Bray F

    Global patterns and trends in colorectal cancer incidence and mortality.

    Gut. 66: 683-691
  • 4.
    • Ait Ouakrim D
    • Pizot C
    • Boniol M
    • et al.

    Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database.

    BMJ. 351h4970
  • 5.
    • Siegel RL
    • Fedewa SA
    • Anderson WF
    • et al.

    Colorectal cancer incidence patterns in the United States, 1974–2013.

    J Nat Cancer Inst. 109djw322
  • 6.
    • Bailey CE
    • Hu CY
    • You YN
    • et al.

    Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010.

    JAMA Surgery. 150: 17-22
  • 7.
    • Wolf AMD
    • Fontham ETH
    • Church TR
    • et al.

    Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.

    CA Cancer J Clin. 68: 250-281
  • 8.
    • Kasi PM
    • Shahjehan F
    • Cochuyt JJ
    • Li Z
    • Colibaseanu DT
    • Merchea A

    Rising proportion of young individuals with rectal and colon cancer.

    Clin Colorectal Cancer. 18: e87-e95
  • 9.
    • Henrikson NB
    • Webber EM
    • Goddard KA
    • et al.

    Family history and the natural history of colorectal cancer: systematic review.

    Genet Med. 17: 702-712
  • 10.
    • Schoen RE
    • Razzak A
    • Yu KJ
    • et al.

    Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer.

    Gastroenterology. 149 (): 1438
  • 11.
    • Czene K
    • Lichtenstein P
    • Hemminki K

    Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database.

    Int J Cancer. 99: 260-266
  • 12.
    • Lichtenstein P
    • Holm NV
    • Verkasalo PK
    • et al.

    Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland.

    N Engl J Med. 343: 78-85
  • 13.
    • Jiao S
    • Peters U
    • Berndt S
    • et al.

    Estimating the heritability of colorectal cancer.

    Hum Mol Genet. 23: 3898-3905
  • 14.
    • Syngal S
    • Brand RE
    • Church JM
    • et al.

    ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes.

    Am J Gastroenterol. 110 (): 223-262
  • 15.
    • Jess T
    • Rungoe C
    • Peyrin-Biroulet L

    Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies.

    Clin Gastroenterol Hepatol. 10: 639-645
  • 16.
    • Brenner H
    • Chang-Claude J
    • Seiler CM
    • Rickert A
    • Hoffmeister M

    Protection from colorectal cancer after colonoscopy: a population-based, case-control study.

    Ann Intern Med. 154: 22-30
  • 17.
    • Cottet V
    • Jooste V
    • Fournel I
    • Bouvier AM
    • Faivre J
    • Bonithon-Kopp C

    Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study.

    Gut. 61: 1180-1186
  • 18.
    • Vasen HF
    • Blanco I
    • Aktan-Collan K
    • et al.

    Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.

    Gut. 62: 812-823
  • 19.
    • Botteri E
    • Iodice S
    • Bagnardi V
    • Raimondi S
    • Lowenfels AB
    • Maisonneuve P

    Smoking and colorectal cancer: a meta-analysis.

    JAMA. 300: 2765-2778
  • 20.

    Cai S, Li Y, Ding Y, Chen K, Jin M. Alcohol drinking and the risk of colorectal cancer death: a meta-analysis. Eur J Cancer Prev; 23: 532–39.

  • 21.
    • Kyrgiou M
    • Kalliala I
    • Markozannes G
    • et al.

    Adiposity and cancer at major anatomical sites: umbrella review of the literature.

    BMJ. 356: j477
  • 22.
    • Chan DS
    • Lau R
    • Aune D
    • et al.

    Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies.

    PLoS One. 6e20456
  • 23.
    • Kramer HU
    • Schottker B
    • Raum E
    • Brenner H

    Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences.

    Eur J Cancer. 48: 1269-1282
  • 24.
    • Nakatsu G
    • Li X
    • Zhou H
    • et al.

    Gut mucosal microbiome across stages of colorectal carcinogenesis.

    Nat Commun. 68727
  • 25.
    • Kwong TNY
    • Wang X
    • Nakatsu G
    • et al.

    Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer.

    Gastroenterology. 155 (): 383
  • 26.
    • Kostic AD
    • Chun E
    • Robertson L
    • et al.

    Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.

    Cell Host Microbe. 14: 207-215
  • 27.

    Cancer stem cells: the challenges ahead.

    Nat Cell Biol. 15: 338-344
  • 28.

    Cancer stem cells: basic concepts and therapeutic implications.

    Ann Rev Pathol. 11: 47-76
  • 29.
    • de Sousa e Melo F
    • Kurtova AV
    • Harnoss JM
    • et al.

    A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer.

    Nature. 543: 676-680
  • 30.
    • Shimokawa M
    • Ohta Y
    • Nishikori S
    • et al.

    Visualization and targeting of LGR5(+) human colon cancer stem cells.

    Nature. 545: 187-192
  • 32.
    • Cancer Genome Atlas Network

    Comprehensive molecular characterization of human colon and rectal cancer.

    Nature. 487: 330-337
  • 33.
    • Loree JM
    • Pereira AAL
    • Lam M
    • et al.

    Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes.

    Clin Cancer Res. 24: 1062-1072
  • 34.
    • Venook AP
    • Niedzwiecki D
    • Innocenti F
    • et al.

    Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance).

    J Clin Oncol. 34 3504
  • 35.
    • Guinney J
    • Dienstmann R
    • Wang X
    • et al.

    The consensus molecular subtypes of colorectal cancer.

    Nat Med. 21: 1350-1356
  • 36.
    • Lee MS
    • Menter DG
    • Kopetz S

    Right versus left colon cancer biology: integrating the consensus molecular subtypes.

    J Natl Compr Canc Netw. 15: 411-419
  • 37.
    • Fijten GH
    • Starmans R
    • Muris JW
    • Schouten HJ
    • Blijham GH
    • Knottnerus JA

    Predictive value of signs and symptoms for colorectal cancer in patients with rectal bleeding in general practice.

    Fam Pract. 12: 279-286
  • 38.
    • Corley DA
    • Jensen CD
    • Marks AR
    • et al.

    Adenoma detection rate and risk of colorectal cancer and death.

    N Engl J Med. 370: 1298-1306
  • 39.
    • Shaukat A
    • Rector TS
    • Church TR
    • et al.

    Longer withdrawal time is associated with a reduced incidence of interval cancer after screening colonoscopy.

    Gastroenterology. 149: 952-957
  • 40.
    • Kaminski MF
    • Regula J
    • Kraszewska E
    • et al.

    Quality indicators for colonoscopy and the risk of interval cancer.

    N Engl J Med. 362: 1795-1803
  • 42.
    • Beets-Tan RGH
    • Lambregts DMJ
    • Maas M
    • et al.

    Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.

    Eur Radiol. 28: 1465-1475
  • 43.
    • Nerad E
    • Lahaye MJ
    • Maas M
    • et al.

    Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis.

    AJR Am J Roentgenol. 207: 984-995
  • 44.
    • Benson 3rd, AB
    • Venook AP
    • Al-Hawary MM
    • et al.

    NCCN guidelines insights: colon cancer, version 2.2018.

    J Natl Compr Canc Netw. 16: 359-369
  • 45.
    • Labianca R
    • Nordlinger B
    • Beretta GD
    • et al.

    Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.

    Ann Oncol. 24: 64-72
  • 46.
    • Pagès F
    • Mlecnik B
    • Marliot F
    • et al.

    International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

    Lancet. 391: 2128-2139
  • 47.
    • Sargent DJ
    • Marsoni S
    • Monges G
    • et al.

    Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

    J Clin Oncol. 28: 3219-3226
  • 48.
    • Le DT
    • Durham JN
    • Smith KN
    • et al.

    Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

    Science. 357: 409-413
  • 49.
    • Douillard JY
    • Oliner KS
    • Siena S
    • et al.

    Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

    N Engl J Med. 369: 1023-1034
  • 50.
    • Schirripa M
    • Cohen SA
    • Battaglin F
    • Lenz HJ

    Biomarker-driven and molecular targeted therapies for colorectal cancers.

    Semin Oncol. 45: 124-132
  • 51.
    • Taieb J
    • Le Malicot K
    • Shi Q
    • et al.

    Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer.

    J Nat Cancer Inst. 109djw272
  • 52.
    • Hayashi N
    • Tanaka S
    • Hewett DG
    • et al.

    Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification.

    Gastrointest Endosc. 78: 625-632
  • 53.
    • Sano Y
    • Tanaka S
    • Kudo SE
    • et al.

    Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI expert team.

    Dig Endosc. 28: 526-533
  • 54.
    • Backes Y
    • Schwartz MP
    • Ter Borg F
    • et al.

    Multicentre prospective evaluation of real-time optical diagnosis of T1 colorectal cancer in large non-pedunculated colorectal polyps using narrow band imaging (the OPTICAL study).

    Gut. 68: 271-279
  • 55.
    • Bhurwal A
    • Bartel MJ
    • Heckman MG
    • et al.

    Endoscopic mucosal resection: learning curve for large nonpolypoid colorectal neoplasia.

    Gastrointest Endosc. 84 (): 959
  • 56.
    • Ferlitsch M
    • Moss A
    • Hassan C
    • et al.

    Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline.

    Endoscopy. 49: 270-297
  • 57.
    • Jayanna M
    • Burgess NG
    • Singh R
    • et al.

    Cost analysis of endoscopic mucosal resection vs surgery for large laterally spreading colorectal lesions.

    Clin Gastroenterol Hepatol. 14 (): 271
  • 58.
    • Ahlenstiel G
    • Hourigan LF
    • Brown G
    • et al.

    Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon.

    Gastrointest Endosc. 80: 668-676
  • 59.
    • Law R
    • Das A
    • Gregory D
    • et al.

    Endoscopic resection is cost-effective compared with laparoscopic resection in the management of complex colon polyps: an economic analysis.

    Gastrointest Endosc. 83: 1248-1257
  • 60.
    • Raju GS
    • Lum PJ
    • Ross WA
    • et al.

    Outcome of EMR as an alternative to surgery in patients with complex colon polyps.

    Gastrointest Endosc. 84: 315-325
  • 61.
    • Keswani RN
    • Law R
    • Ciolino JD
    • et al.

    Adverse events after surgery for nonmalignant colon polyps are common and associated with increased length of stay and costs.

    Gastrointest Endosc. 84: 296-303.e1
  • 62.

    Completing the circle of informed consent for EMR versus surgery for nonmalignant large or complex colorectal polyps.

    Gastrointest Endosc. 84: 304-306
  • 63.
    • Bondeven P
    • Hagemann-Madsen RH
    • Laurberg S
    • Pedersen BG

    Extent and completeness of mesorectal excision evaluated by postoperative magnetic resonance imaging.

    Br J Surg. 100: 1357-1367
  • 64.

    Complete mesocolic excision and extended (D3) lymphadenectomy for colonic cancer: is it worth that extra effort? A review of the literature.

    Int J Colorectal Dis. 31: 797-804
  • 65.
    • Cleary RK
    • Morris AM
    • Chang GJ
    • Halverson AL

    Controversies in surgical oncology: does the minimally invasive approach for rectal cancer provide equivalent oncologic outcomes compared with the open approach?.

    Ann Surg Oncol. 25: 3587-3595
  • 66.
    • Jayne D
    • Pigazzi A
    • Marshall H
    • et al.

    Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial.

    JAMA. 318: 1569-1580
  • 67.

    Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision.

    BMC Cancer. 16: 380
  • 68.

    What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients.

    Int J Cancer. 141: 1052-1065
  • 69.
    • Taylor FG
    • Quirke P
    • Heald RJ
    • et al.

    Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.

    Ann Surg. 253: 711-719
  • 70.
    • Glynne-Jones R
    • Wyrwicz L
    • Tiret E
    • et al.

    Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.

    Ann Oncol. 29: 22-40
  • 71.
    • Du D
    • Su Z
    • Wang D
    • Liu W
    • Wei Z

    Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.

    Clin Colorectal Cancer. 17: 13-24
  • 72.
    • Lefevre JH
    • Mineur L
    • Kotti S
    • et al.

    Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6).

    J Clin Oncol. 34: 3773-3780
  • 73.
    • Erlandsson J
    • Holm T
    • Pettersson D
    • et al.

    Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

    Lancet Oncol. 18: 336-346
  • 74.
    • Bisschop C
    • van Dijk TH
    • Beukema JC
    • et al.

    Short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary stage IV rectal cancer: long-term results of a phase II study.

    Ann Surg Oncol. 24: 2632-2638
  • 75.
    • van der Valk MJM
    • Hilling DE
    • Bastiaannet E
    • et al.

    Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

    Lancet. 391: 2537-2545
  • 76.
    • Stijns RCH
    • de Graaf EJR
    • Punt CJA
    • et al.

    Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study.

    JAMA Surg. 154: 47-54
  • 77.
    • Rullier E
    • Rouanet P
    • Tuech J-J
    • et al.

    Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.

    Lancet. 390: 469-479
  • 78.
    • Ryan JE
    • Warrier SK
    • Lynch AC
    • Ramsay RG
    • Phillips WA
    • Heriot AG

    Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.

    Colorectal Dis. 18: 234-246
  • 79.

    Integrating systemic therapies into the multimodality treatment of resectable colorectal liver metastases.

    Gastroenterol Res Pract. 20184326082
  • 80.
    • Baratti D
    • Kusamura S
    • Pietrantonio F
    • Guaglio M
    • Niger M
    • Deraco M

    Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review.

    Crit Rev Oncol Hematol. 100: 209-222
  • 81.
    • Andre T
    • Boni C
    • Navarro M
    • et al.

    Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

    J Clin Oncol. 27: 3109-3116
  • 82.
    • Haller DG
    • Tabernero J
    • Maroun J
    • et al.

    Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

    J Clin Oncol. 29: 1465-1471
  • 83.
    • Kuebler JP
    • Wieand HS
    • O'Connell MJ
    • et al.

    Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

    J Clin Oncol. 25: 2198-2204
  • 84.
    • Yothers G
    • O'Connell MJ
    • Allegra CJ
    • et al.

    Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

    J Clin Oncol. 29: 3768-3774
  • 85.
    • Roth AD
    • Tejpar S
    • Delorenzi M
    • et al.

    Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial.

    J Clin Oncol. 28: 466-474
  • 86.
    • Meyers BM
    • Cosby R
    • Quereshy F
    • Jonker D

    Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a cancer care Ontario systematic review.

    Clin Oncol. 29: 459-465
  • 87.
    • Breugom AJ
    • Swets M
    • Bosset J-F
    • et al.

    Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.

    Lancet Oncol. 16: 200-217
  • 88.
    • de Gramont A
    • Van Cutsem E
    • Schmoll H-J
    • et al.

    Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

    Lancet Oncol. 13: 1225-1233
  • 89.
    • Saltz LB
    • Niedzwiecki D
    • Hollis D
    • et al.

    Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

    J Clin Oncol. 25: 3456-3461
  • 90.
    • Van Cutsem E
    • Labianca R
    • Bodoky G
    • et al.

    Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

    J Clin Oncol. 27: 3117-3125
  • 91.
    • Alberts SR
    • Sargent DJ
    • Nair S
    • et al.

    Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

    JAMA. 307: 1383-1393
  • 92.
    • Taieb J
    • Tabernero J
    • Mini E
    • et al.

    Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

    Lancet Oncol. 15: 862-873
  • 93.
    • Grothey A
    • Sobrero AF
    • Shields AF
    • et al.

    Duration of adjuvant chemotherapy for stage III colon cancer.

    N Engl J Med. 378: 1177-1188
  • 94.
    • Falcone A
    • Ricci S
    • Brunetti I
    • et al.

    Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

    J Clin Oncol. 25: 1670-1716
  • 95.
    • Hurwitz H
    • Fehrenbacher L
    • Novotny W
    • et al.

    Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

    N Engl J Med. 350: 2335-2342
  • 96.
    • Saltz LB
    • Clarke S
    • Diaz-Rubio E
    • et al.

    Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

    J Clin Oncol. 26: 2013-2019
  • 97.
    • Cunningham D
    • Lang I
    • Marcuello E
    • et al.

    Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

    Lancet Oncol. 14: 1077-1085
  • 98.
    • Van Cutsem E
    • Tabernero J
    • Lakomy R
    • et al.

    Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

    J Clin Oncol. 30: 3499-3506
  • 99.
    • Tabernero J
    • Yoshino T
    • Cohn AL
    • et al.

    Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

    Lancet Oncol. 16: 499-508
  • 100.
    • Arnold D
    • Lueza B
    • Douillard JY
    • et al.

    Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    Ann Oncol. 28: 1713-1729
  • 101.
    • Bokemeyer C
    • Bondarenko I
    • Makhson A
    • et al.

    Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

    J Clin Oncol. 27: 663-671
  • 102.
    • Van Cutsem E
    • Kohne CH
    • Hitre E
    • et al.

    Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

    N Engl J Med. 360: 1408-1417
  • 103.
    • Bokemeyer C
    • Van Cutsem E
    • Rougier P
    • et al.

    Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

    Eur J Cancer. 48: 1466-1475
  • 104.
    • Douillard JY
    • Siena S
    • Cassidy J
    • et al.

    Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

    J Clin Oncol. 28: 4697-4705
  • 105.
    • Pietrantonio F
    • Cremolini C
    • Petrelli F
    • et al.

    First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

    Crit Rev Oncol Hematol. 96: 156-166
  • 106.
    • Pietrantonio F
    • Petrelli F
    • Coinu A
    • et al.

    Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

    Eur J Cancer. 51: 587-594
  • 107.
    • Heinemann V
    • von Weikersthal LF
    • Decker T
    • et al.

    FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

    Lancet Oncol. 15: 1065-1075
  • 108.
    • Venook AP
    • Niedzwiecki D
    • Lenz HJ
    • et al.

    Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial.

    JAMA. 317: 2392-2401
  • 109.

    Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

    J Clin Oncol. 35 3505
  • 110.
    • Van Cutsem E
    • Huijberts S
    • Grothey A
    • et al.

    Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study.

    J Clin Oncol. 37: 1460-1469
  • 111.
    • Kopetz S
    • Grothey A
    • Yaeger R
    • et al.

    Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer.

    N Engl J Med. ()
  • 112.
    • Grothey A
    • Van Cutsem E
    • Sobrero A
    • et al.

    Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

    Lancet. 381: 303-312
  • 113.
    • Adenis A
    • de la Fouchardiere C
    • Paule B
    • et al.

    Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

    BMC Cancer. 16
  • Read more at the original link...

    0 comments
    Report            

    Read On:

    Are you a doctor? Click here and signup to join medical discussion forums, and receive medical job alerts! Free!

    Medical Jobs

    Tags

      
      
     

    Most Recent

    Doctor? Click here to signup to receive news & research in your specialty